Easing the Pain of Inflammation - Arthritis Vaccine

The Technology

Spondyloarthropathies (SpAs) are a family of inflammatory processes associated with HLA B27 polymorphism that develop into a number of conditions such as fusion of the spine or ankylosing spondylitis (AS), Reiter’s syndrome (or reactive arthritis), psoriatic arthritis, Crohn’s disease (a type of IBD) and uveitis.

Our researchers believe that they have discovered the mechanism of action for SpAs, based on shared homology of specific peptide sequences that occur in Chlamydia trachomatis and also in a protein called lumican which is preferentially and abundantly expressed in the locations where SpAs manifest. The shared peptide sequences have very high binding affinity to HLA B27, allowing the triggering of the immune response.

Investment Opportunity

NewSouth Innovations is looking for a partner to exclusively license the technology and take on the clinical development of the diagnostic as well as the potential vaccine specifically for SpAs.


Lumican staining in human iris pigment epithelial cells (IPE),
iris and synovial tissues. Human IPE cultures (A and E), iris
tissues (B and F), synovial tissues (C-D, G-H) were labelled
with anti-lumican or control rabbit IgG, followed by HRP or
Alexa-fluor conjugated goat anti-rabbit IgG. Lumican staining
(red) is present in IPE in vitro (E) and in vivo (F), in blood
vessels (bv) (G) and in articular cartilage (H). Original
magnification x100 (A, E) and x400 (B-D, F-H).



Please download the PDF of this Technology Brief

Patent Information:
For Information, Contact:
Alfredo Martinez-Coll
Senior Business Development Manager
NewSouth Innovations Pty Ltd
02 9385 4679
a.martinez-coll@unsw.edu.au
Reference ID: 09_2354
Inventors:
Denis Wakefield
Helder Marcal
Keywords:
© 2017. All Rights Reserved. Powered by Inteum